Loading data for TLSA — first visit, this takes a few seconds.

Alerta

Tiziana Life Sciences Ltd (TLSA)

NasdaqCM: TLSA · Precio en tiempo real · USD

1.12

-0.03 (-2.61%)

Al cierre: Aug 18, 2026, 8:00 PM

-2.61% (1D)

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	142.53M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-18.43M
Beta	0.46
EPS (TTM)	-0.16
Ratio PER (TTM)	n/a
Adelante PE	-5.61
P/B (TTM)	14.55
P/S (TTM)	n/a
Earnings Date	n/a

Precio de venta	n/a
Volumen	1,623,547
Volumen medio (20D)	479,979
Abierto	1.14
Anterior Cerrar	1.15
Rango del día	1.06 - 1.17
Rango de 52 semanas	0.87 - 2.35
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de TLSA

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic latera...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Nov 20, 2018

Empleados 10

Bolsa de Valores NasdaqCM

Símbolo bursátil TLSA

Sitio web https://www.tizianalifesciences.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Tiziana Life Sciences Ltd fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -18.43M, un aumento de 55.37%.

Estados financieros

Sorpresa de resultados

Tiziana Life Sciences Ltd ha publicado sus resultados trimestrales en Dec 27, 2022:

Ingresos de n/a falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.06 falla las estimaciones por , con -Infinity% Disminución interanual.

Noticias

2 semanas hace · Proactive

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal fo...

1 mes hace · Proactive

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Mul...

2 meses hace · Motley Fool

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.

2 meses hace · Proactive

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple sclerosis (SPMS), while also reporting expanded a...

2 meses hace · Proactive

Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progress...

Página 1 de 2

Tiziana Life Sciences Ltd (TLSA)